PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Lab Invest. Author manuscript; available in PMC 2010 June 10.
Published in final edited form as:
PMCID: PMC2883308
NIHMSID: NIHMS209834

SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients

Abstract

Recent studies in mice have demonstrated that the protein tyrosine phosphatase SHP-1 is a crucial negative regulator of cytokine signaling, inflammatory gene expression, and demyelination in central nervous system. The present study investigates a possible similar role for SHP-1 in the human disease multiple sclerosis (MS). The levels of SHP-1 protein and mRNA in PBMCs of MS patients were significantly lower compared to normal subjects. Moreover, promoter II transcripts, expressed from one of two known promoters, were selectively deficient in MS patients. To examine functional consequences of the lower SHP-1 in PBMCs of MS patients, we measured the intracellular levels of phosphorylated STAT6 (pSTAT6). As expected, MS patients had significantly higher levels of pSTAT6. Accordingly, siRNA to SHP-1 effectively increased the levels of pSTAT6 in PBMCs of controls to levels equal to MS patients. Additionally, transduction of PBMCs with a lentiviral vector expressing SHP-1 lowered pSTAT6 levels. Finally, multiple STAT6-responsive inflammatory genes were increased in PBMCs of MS patients relative to PBMCs of normal subjects. Thus, PBMCs of MS patients display a stable deficiency of SHP-1 expression, heightened STAT6 phosphorylation, and an enhanced state of activation relevant to the mechanisms of inflammatory demyelination.

Keywords: autoimmunity, demyelination, inflammation, STAT6

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that remains a major cause of disability.1,2 Several studies demonstrate that MS lesions and PBMCs from MS patients contain activated transcription factors like NF-κB, STAT1, STAT3, and STAT6,3-5 which can lead to enhanced signaling of inflammatory stimuli. These findings suggest that regulation of inflammatory signaling may be altered in MS and may be responsible for inflammatory demyelination.

SHP-1 is a protein tyrosine phosphatase with two SH2 domains and acts as a negative regulator of cytokine signaling via STAT1, STAT3, and STAT6.6-9 We have shown that mice genetically lacking in SHP-1 (motheaten mice) display myelin deficiency, which may be mediated by increased inflammatory mediators in the CNS.10,11 Furthermore, when motheaten mice are infected with Theiler’s murine encephalomyelitis virus (TMEV), the CNS displays substantially more virus-induced inflammatory demyelination than wild-type mice.12 In agreement with these studies, lower levels of SHP-1 have also been implicated in autoimmune-mediated demyelination in rodents12,13 and in lymphoproliferative diseases in humans.14-17 Moreover, low SHP-1 levels have been associated with excessive tyrosine phosphorylation of STAT1 following IFN-β treatment in MS patients.18 These studies suggest that SHP-1 plays multiple roles in leukocytes, including controlling activation state relevant to mechanisms of inflammatory demyelination.

Two distinct promoters are responsible for expression of each of the two known SHP-1 transcripts produced from the SHP-1 gene.19 These distinct transcripts in turn encode two slightly different SHP-1 isoforms, which have the same catalytic activity.20 It was previously shown that the two SHP-1 transcripts are differentially expressed in human tissues and cell lines.21,22 Promoter I transcripts are highly expressed in epithelial cells, while promoter II transcripts are more abundant in hematopoietic cells.22,23 Several reports show differential regulation of the SHP-1 gene promoters by distinct transcription factors.19,24,25 Importantly, promoter-specific regulation of SHP-1 expression has been associated with human disease.14,23,26

In this study, we show that the levels of SHP-1 are lower in PBMCs from MS patients compared to normal subjects. Corresponding to this deficiency, we have shown that STAT6 phosphorylation and STAT6-responsive genes are constitutively higher in PBMCs of MS patients compared to those of normal subjects. Additionally, we delineate the contribution of two promoter-specific transcripts in SHP-1 deficiency, which points to a specific decrease in promoter II activity in PBMCs of MS patients. Taken together, we propose the potential involvement of SHP-1 promoter II dysregulation in the pathogenesis of MS.

MATERIALS AND METHODS

Patient Selection

Patients were clinically diagnosed as either having active relapsing–remitting (RR) MS, active secondary progressive (SP) MS, or inactive RR (Inc) MS.27 Active RR MS was defined as a moderate to severe exacerbation within 6 months prior to entry and SP MS was defined as a continuous progression over the preceding 6 months of the study. Patients who had not received any disease-modifying treatment like IFN-β, glatiramir acetate, or other immunosuppressive agents at least two months prior to donating blood were selected. In this study, PBMCs were isolated from 23 MS patients, and 18 control subjects. The Institutional Review Board of SUNY Upstate University approved all studies, and both patients and controls granted informed consent before providing blood.

PBMC Isolation and Expansion

Patients and normal subjects donated 50 ml of blood collected in heparinized tubes. Blood was diluted 1:1 with HBSS and overlaid onto lymphocyte separation medium (Cellgro, Herndon, VA, USA). After centrifugation, 10 ml of the interface containing the PBMCs was collected and diluted to 50 ml with HBSS. After another two washes with HBSS, a sample of the freshly isolated cells was resuspended in STAT-60 (Tel-Test, Friendswood, TX, USA) for RNA analysis. The rest of the cells were cultured for a week in RPMI media with 20 U/ml IL-2 (R&D Systems, Minneapolis, MN, USA) and 10% fetal bovine serum. After 1 week, cells were either resuspended in STAT-60 or in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 mM activated Na3VO4) for protein analysis or fixed for intracellular flow analysis. In all experiments, PBMCs, either freshly isolated or cultured for a week in the presence of IL-2, were used with exception to lentiviral vector transductions. In the lentiviral vector transduction experiments, cells were incubated for 25 days to allow the vector to integrate into the host DNA and expand the number of transduced cells.

Cytokine and siRNA Treatment

PBMCs of MS patients and normal subjects were cultured for 1 week and were then treated with either 10 ng/ml of IL-4 for 24 h or received medium alone (R&D Systems). A portion of PBMCs were transfected with siRNA against human SHP-1 or scramble siRNA (Dharmacon, Chicago, IL, USA) at a concentration of 1 μg/106 cells. The transfection reagent (Dharmafect 4; Dharmacon) was used as specified by the manufacturer. Cells were incubated in the transfection medium for 24 h, after which the medium was replaced with complete growth medium for another 48 h before IL-4 treatment. The effectiveness of the SHP-1 siRNA to lower SHP-1 expression was evaluated by both real-time RT-PCR and flow cytometry.

Real-Time RT-PCR

Total RNA was isolated using RNA STAT-60. RNA was quantified spectrophotometrically and 0.5 μg of total RNA was converted into cDNA. Briefly, total RNA and random primers (Invitrogen, Carlsbad, CA, USA) were incubated at 72°C for 10 min. Reverse transcription was performed using the Superscript II RT enzyme (Invitrogen) following the specification of the manufacturer. cDNA was diluted to 200 μl with water and 4 μl was used for quantitative real-time PCR using SYBR Green kit (Abgene, Epson, UK). The PCR parameters were 15 min for 95°C and 35 cycles of 95°C for 15 s and 60°C for 1 min in ABI prism 700 (Applied Biosystems, Foster city, CA, USA). The primers were used at 10 nM. Serial dilutions of cDNA containing a known copy number of each gene were used in each quantitative PCR run to generate a standard curve relating copy number with threshold amplification cycle.28 Gene expression levels were calculated during the logarithmic amplification phase by determining the initial mRNA copy number using the standard curve. Amplification of each gene-specific fragment was confirmed both by examination of melting peaks and by agarose gel electrophoresis. The following primer pairs were used in this study: SHP-1 (BC002523) forward-TGGCGTGGCAGGAGAACAG and reverse-GCAGTTGGTCACAGAGTAGGGC, SHP-1 (I) (NM080548) forward-TGGCTTCCCCCTCCCTACAG and reverse-CCCTGGTTCTTGCGACTGG, SHP-1 (II) (NM002831) forward-ATCTGAGGCTTAGTCCCTGAGC and reverse-CTGAGGTCTCGGTGAAACCAC, IL-4 (NM000589) forward-TCCCAACTGCTTCCCCC and reverse-TCTTCTGCTCTGTGAGGCTG, IL-4rα (IL-4rα) forward-CGTGTATCCCTGAGAACAACG and reverse-CGTGTATCCCTGAGAACAACG, CCL17 (NM002987) forward-CGAGGGACCAATGTGGGC and reverse-GGGTGAGGAGGCTTCAAGACC, CCL11 (NM002986) forward-CACTTCTGTGGCTGCTGCTC and reverse-GCTTTCTGGGGACATTTGC, CCR4 (NM005508) forward-GGTCCTGTTCAAATACAAGCG and reverse-AAACCCACTGGTCTGCTGC, CCR8 (NM005201) forward-CAGTGTGACAACAGTGACCGAC and reverse-GCAATAAAAGACAGCAAGGAGC, ADAM8 (NM001109) forward-ATCCCGAGAGACCCGCTAC and reverse-TGATTCACCACCTCCAGCAC, lymphotoxin-α (LTα) (NM000595) forward-CACCTCATTGGAGACCCCAG and reverse-TGTTGCTCAAGGAGAAACCATC, Arginase I (NM000045) forward-GACCTGCCCTTTGCTGACATC and reverse-TTGACTTCTGCCACCTTGCC, IFN-γ (NM000619) forward-TGCAGGTCATTCAGATGTAG and reverse-AGCCATCACTTGGATGAGTT, MCP-1 (NM002982) forward-GCTCATAGCAGCCACCTTC and reverse-GCTTCTTTGGGACACTTGC, GAPDH (NM002046) forward-ACCACCATGGAGAAGGC and reverse-GGCATGGACTGTGGTCATGA.

Western Blotting

Whole-cell extracts were prepared as previously described.9,29 Briefly, PBMCs were rinsed with PBS, and then lysed with RIPA buffer. Protein (100 μg) per lane was electrophoresed through a 7.5% polyacrylamide-resolving gel and electroblotted to a polyvinylidene difluoride membrane (Millipore Corporation, Burlington, MA, USA). Membranes were blocked with 5% non-fat dry milk for 1 h, and then incubated with anti-SHP-1 (Upstate, Lake Placid, NY) antibodies followed by horseradish peroxidase-conjugated rabbit IgG antibody (Dako Corporation, Carpinteria, CA, USA). Enhanced chemiluminescence (Amersham Life Sciences Inc., Cleveland, OH, USA) was used to visualize reactive protein bands on X-ray film.

Sorting and Flow Cytometry

Percentage analysis of PBMC cell types by flow cytometry

PBMCs were sorted into the different cell populations (T cells, B cells, and monocytes) to examine the expression of SHP-1 in individual populations. Cells (4 × 106/200 μl) were incubated on ice for 30 min with 20 μl of CD3-FITC (349201) to stain T cells, 20 μl of CD19-PE (340720) to stain B cells, and 10 μl of CD14-APC (340684) to stain for monocytes (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA). Cells were washed and resuspended in 1mL of Hank’s solution and were analyzed by fluorescence-activated cell sorter (FACS Vantage S/E; Becton Dickinson). The percentage of each cell population was determined and four aliquots labeled as T cells, B cells, monocytes, and negative cells were collected. The cells of each aliquot were lysed in the RNA isolation reagent.

Intracellular pSTAT6 flow cytometric analysis

PBMCs were treated for 15 min with 10ng/ml IL-4. Cells (106/1 ml) received 100 μl of 16% stock formaldehyde for fixation and then incubated in 90% methanol at 4°C for half an hour to permeabilize cells for intracellular staining. Cells were washed twice with the staining media containing 0.5% BSA and 0.02% sodium azide in PBS. Cells were resuspended in a 100 μl of staining media and incubated with 20 μl either phosphoSTAT6 (PY-641) with Alexa-488 (612600), CD3-FITC (349201), or mouse IgG with Allexa-488 isotype control (557721) (Becton Dickinson).

Intracellular SHP-1 flow cytometric analysis

Also, the levels of SHP-1 were concurrently analyzed with pSTAT6. Fixed and permeabilized cells were incubated overnight at 4°C with either 1μg of rabbit anti-SHP-1 (Upstate), rabbit anti-total STAT6 (phosphorylated plus unphosphorylated) (Santa Cruz Biotech., Inc., Santa Cruz, CA, USA) antibodies, or rabbit polyclonal IgGs for isotype control. The cells were incubated for 3 h in 1 μg of goat anti-rabbit secondary antibody conjugated to PE (Invitrogen). Cells were analyzed on an LSRII analyzer (Becton Dickinson) and the mean florescence intensity (MFI) was recorded. To quantify the levels of STAT6-responsive genes by flow cytometry, anti-human ADAM8-PE IgG (R&D Systems; Cat no. 143338) was used to stain ADAM8 and anti-human LTα (R&D Systems; Cat no. 5808) was used to stain LTα (R&D Systems). Fixed and permeabilized cells were stained for 45 min at room temperature and analyzed. To quantify the levels of CCL17/TARC, cells were treated with 5 mg/ml of Brefeldin-A prior to fixation to block chemokine secretion and after 12 h cells were fixed and stained with anti-human CCL17/TARC (R&D Systems; Cat no. 54015) for 45 min and then analyzed.

Transduction of SHP-1-Expresssing Lentiviral Vector

The lentiviral vector prepared as described30 was used to stably infect PBMCs of MS patients. The vector carried the human SHP-1 coding sequence (NCBI no. BC002523), allowing the bicistronic expression of green fluorescent protein (GFP) and SHP-1 in the transduced cells. PBMCs were incubated in RPMI medium and infected at an approximate MOI of 0.1 for 16 h. The virus was then removed and the cells were cultured for 25 days both to allow stable integration of the lentiviral DNA in the host DNA and expand the number of transduced cells. Transduced PBMCs of MS patients and control PBMCs of normal subjects’ cells were incubated in IL-2-containing medium to maintain cell variability for the culture period. Cell viability was assessed by cell morphology and Trypan blue exclusion. GFP expression was analyzed with flow cytometry and GFP-expressing cells were sorted using FACS (Becton Dickinson). The GFP-positive and -negative cells were analyzed for the expression of SHP-1 and pSTAT6 using flow cytometry and the expression of several STAT6-responsive genes using real-time RT-PCR.

Arginase Activity Assay

Arginase enzymatic activity was measured as previously described.31 Briefly, PBMCs were lysed in RIPA buffer and incubated in 10 mM MnCl2 and 0.5 M l-arginine at 37°C for 75 min. After the assay was stopped by addition of H3PO4, 1-phenyl-1,2-propanedione-2-oxime (Sigma, St Louis, MO, USA) was added and the samples were incubated at 100°C for 60 min. Urea production by arginase was measured by optical density at 540 nm.

Statistical Analysis

Histograms or tables contain statistical means with the standard error values. The number of samples used in each assay is indicated in the figure legends. The P-values were generated using the unpaired Student’s t-test and a P-value of less than 0.05 was chosen to indicate statistical significance between two sample means.

RESULTS

SHP-1 Protein and mRNA are lower in MS Patients

To examine SHP-1 expression in MS patients, isolated PBMCs were prepared from whole heparinized human blood. The levels of SHP-1 mRNA were quantified using primers flanking the coding region of the gene common to both transcripts. SHP-1 mRNA levels in freshly isolated PBMCs were significantly lower in MS patients compared to normal subjects (Figure 1a). To examine whether the SHP-1 deficiency in PBMCs of MS patients was stable, PBMCs were expanded for 1 week in vitro. Similarly, SHP-1 mRNA was significantly lower in cultured PBMCs of MS patients compared to those of normal subjects (Figure 3a). Moreover, the levels of SHP-1 mRNA did not differ between PBMCs of MS patients who were clinically diagnosed with either RR MS or SP MS, indicating that depressed SHP-1 was a general marker across these clinical subclassifications (Figure 4). In accordance with mRNA levels, PBMCs of MS patients had significantly lower levels of SHP-1 protein than those of normal subjects measured by western immunoblotting (Figures 2a and b). To corroborate these findings, the levels of SHP-1 protein in PBMCs were measured by intracellular flow cytometry (Figures 2c and d). Constitutive levels of SHP-1 in PBMCs of MS patients were half the levels of SHP-1 in cells of normal subjects. Analysis of protein (Figure 2a) and mRNA (Figure 3b) of housekeeping genes showed no differences between MS and normal subject PBMCs.

Figure 1
SHP-1 mRNA levels in freshly isolated PBMCs of MS patients and normal subjects. The absolute mRNA transcript copy numbers per 10 ng of total RNA were quantified using real-time RT-PCR in MS patients (n = 23) and normal subjects (n = 18). (a) Using primers ...
Figure 2
SHP-1 protein expression in cultured PBMCs of MS patients compared to normal subjects. (a) Western blot analysis of SHP-1 and actin in PBMCs of MS patients compared to normal subjects. (b) The Western immunoblot protein bands of MS patients (n = 7) and ...
Figure 3
SHP-1 mRNA levels in cultured PBMCs of MS patients compared to normal subjects. The absolute mRNA transcript copy numbers per 10 ng of total RNA were quantified using real-time RT-PCR in MS patients (n = 23) and normal subjects (n = 18). (a) The levels ...
Figure 4
SHP-1 mRNA levels in freshly isolated (a–d) or cultured (e–h) PBMCs of patients diagnosed with different clinical subclassifications of MS. The absolute specific mRNA transcript numbers per 10 ng of total RNA were quantified with real-time ...

SHP-1 Promoter II Transcripts are Selectively Lower in MS Patients

To determine the individual contribution of each of two known transcripts on the expression levels of SHP-1 in PBMCs, promoter I and II transcript copy numbers were measured using promoter-specific RT-PCR primers. Constitutive levels of SHP-1 promoter I and GAPDH transcripts were not significantly lower in PBMCs of MS patients compared to controls (Figures (Figures1c,1c, 3b and 3c). On the other hand, constitutive levels of SHP-1 promoter II transcripts were two-fold lower in PBMCs of MS patients compared to controls (Figures (Figures1d1d and and3d).3d). Additionally, the levels of SHP-1 transcripts I and II did not differ between PBMCs of MS patients with different clinical subclassifications (Figure 4). Taken together, we concluded that PBMCs of MS patients have constitutively lower levels of SHP-1 protein and mRNA compared to normal subjects and furthermore that a lack of promoter II transcripts is primarily responsible for this deficiency.

Expression of SHP-1 in Specific PBMC Types

To determine whether the lower levels of SHP-1 seen in PBMCs of MS patients could be attributed to differences in the proportions of cell types between subjects, we analyzed SHP-1 expression in sorted PBMCs. Antibodies against CD3, CD19, and CD14 were used to separate PBMCs into T cells, B cells, and monocytes, respectively. The percentage of each cell population was measured in PBMCs and RNA was isolated from the sorted fractions to measure the levels of SHP-1. The proportion of cell types making up the PBMCs of MS patients and controls were the same (80% T cells, 5% B cells, 3% monocytes, and 12% of negative cells). A majority of negative cells probably represent natural killer cells based on their scatter properties.32

The levels of SHP-1 mRNA in the sorted populations were quantified and T cells had similar levels of SHP-1 as in unsorted PBMCs. Importantly, T-cell populations of MS patients had significantly lower levels of SHP-1 compared to normal subjects (Figure 5a), similar to that seen in the unsorted population. Additionally, B cells and unstained cells of MS patients had significantly lower levels of SHP-1 mRNA compared to the same cell types of normal subjects. As expected, SHP-1 promoter II transcripts were primarily responsible for the lower levels of SHP-1 in MS patients in the sorted populations with more dramatic differences seen in B cells and negative cells (six-fold lower in MS compared to normal subjects). T cells had a three-fold lower level of SHP-1 promoter II transcripts in MS patients compared to normal subjects (Figure 5d). In contrast, promoter I and GAPDH transcripts were not significantly different in either unsorted PBMCs or sorted cell populations of MS patients compared to normal subjects (Figures 5b and c). These data indicate that MS patients and normal subjects contain similar proportions of leukocytes; however, the levels of SHP-1 expression in specific mononuclear cell populations are significantly lower in MS patients compared to normal subjects.

Figure 5
Quantification of the SHP-1 mRNA in different cell types of MS patients and normal subjects. The absolute mRNA transcript copy numbers per 10 ng of total RNA were quantified with real-time RT-PCR in MS patients (n = 23) and normal subjects (n = 18). Cultured ...

Analysis of STAT6 Activation in MS PBMCs

SHP-1 regulates phosphorylation of several STATs by removal of the phosphate group from tyrosine either on activated cytokine receptors or downstream signaling molecules. Thus, SHP-1 modulates STAT activation, translocation into the nucleus, and transcriptional activity on responsive genes. Because several studies showed that SHP-1 profoundly modulates IL-4R/STAT6 signaling molecules,33-36 STAT6 was chosen for further analysis of possible altered function of SHP-1 in MS PBMC. For analysis, we measured the levels of total STAT6 (unphosphorylated plus phosphorylated, tSTAT6) and tyrosine phosphorylated STAT6 (pSTAT6) in PBMCs using intracellular flow cytometry. As expected, PBMCs of MS patients had significantly elevated constitutive phosphorylation of STAT6 compared to PBMCs of normal subjects (Figure 6c). In contrast, there were no differences in the expression levels of total STAT6 protein (Figures 6a and b), verifying that the differences observed in pSTAT6 levels are attributed to the relative phosphorylation state of STAT6. Staining the same cells for SHP-1 revealed a reciprocal expression pattern of SHP-1 and pSTAT6, such that lower constitutive levels of SHP-1 in MS patients correlated with higher pSTAT6 levels compared to PBMCs of normal subjects (Figure 7). Furthermore, PBMCs were treated with IL-4 to determine possible differences in STAT6 activation following engagement of the IL-4 receptor. Treatment with IL-4 caused higher phosphorylation of STAT6 in PBMCs of MS patients compared to normal subjects (Figure 6d).

Figure 6
Total STAT6 and phosphorylated STAT6 (pSTAT6) levels in cultured PBMCs of MS patients compared to normal subjects. PBMCs from MS patients and normal controls were fixed, permeabilized, and stained with antibodies against either total STAT6 (unphosphorylated ...
Figure 7
pSTAT6 levels in PBMCs after siRNA treatment against SHP-1. Cultured PBMCs from MS patients and normal subjects were stained with antibodies against the phosphorylated form of STAT6 (pSTAT6) or against SHP-1. The histogram overlays are labeled as follows: ...

To directly determine whether a specific deficiency in SHP-1 could mediate increased activation of STAT6 in human PBMCs, PBMCs of patients and controls were treated with siRNA against SHP-1 and levels of pSTAT6 were measured. The efficiency of the siRNA against SHP-1 was verified by both real-time RT-PCR and intracellular flow cytometry (Figure 7a and Table 1). SHP-1 siRNA treatment effectively increased the levels of pSTAT6 in PBMCs of normal subjects to levels equal that of MS patients. Also, SHP-1 siRNA significantly increased inducible pSTAT6 levels following IL-4 treatment (Figure 7d). These results indicate that lower SHP-1 in PBMCs of MS patients could be directly responsible for higher constitutive levels of pSTAT6 and heightened IL-4-induced signaling to STAT6.

Table 1
Gene profile of PBMCs of MS patients and normal subjects

As a reciprocal approach, PBMCs of MS patients were transduced with a lentiviral expression vector carrying the human SHP-1 coding sequence, which allowed the bicistronic expression of GFP and SHP-1. PBMCs were then sorted according to GFP expression and were stained for SHP-1 and pSTAT6. Cells expressing GFP expressed heightened SHP-1 and lower pSTAT6 levels compared to cells in the same culture that did not express GFP (Figure 9), further substantiating that lower SHP-1 as seen in MS patients directly leads to increased pSTAT6 levels.

Figure 9
PBMCs of MS patients were transduced with a lentiviral vector co-expressing GFP and SHP-1. Cells were sorted into two populations, GFP negative (solid line) or GFP positive (dashed line). The sorted aliquots were then analyzed for the expression of ( ...

Heightened Expression of STAT6-Inducible Genes in MS

To determine whether constitutively higher pSTAT6 in PBMCs of MS patients relative to PBMCs of normal subjects corresponded to heightened expression of STAT6-responsive genes, the mRNA levels of several genes that are STAT6 responsive were measured in PBMCs of MS patients, normal subjects, and normal subjects treated with siRNA against SHP-1. The expression levels of certain STAT6-responsive chemokines and their receptors were of particular interest because these mediate trafficking, maturation, and attraction of T cells and macrophages to areas of CNS inflammation.37 CCL17/TARC38,39 was highly expressed in PBMCs and was more than five-fold higher in PBMCs of MS patients compared to normal subjects measured by both real-time RT-PCR and flow cytometry (Table 1 and Figure 8a). Treatment with siRNA to SHP-1 tripled the constitutive amount of CCL17/TARC in PBMCs of normal subjects, indicating that SHP-1 regulated CCL17/TARC expression. Treatment with IL-4 for 24 h induced significantly higher levels of CCL17/TARC in PBMCs of MS patients compared to PBMCs of normal subjects. Moreover, SHP-1 siRNA-treated PBMCs of normal subjects had heightened expression of CCL17/TARC in response to IL-4. Furthermore, transduction of the SHP-1-expressing vector in PBMCs of MS patients (Figure 9) decreased CCL17 expression by 15-fold (Table 2).

Figure 8
Protein levels of STAT6-inducible genes in MS patients were verified using flow cytometry and enzymatic assays. (a) CCL17/TARC, (b) ADAM8 and (c) lymphotoxin-α protein levels were measured using flow cytometry in cultured PBMCs of MS patients ...
Table 2
Regulation of STAT6-inducible genes in PBMCs of MS patients after overexpressing SHP-1

Another STAT6-responsive chemokine, CCL11/eotaxin,40 was significantly higher in MS patient PBMCs and normal subject PBMCs treated with SHP-1 siRNA than in PBMCs of normal subjects (Table 1). When the mRNA transcript levels of two of the chemokine receptors CCR4 and CCR8 that bind the CCL17/TARC and CCL11/eotaxin ligands were measured,14 CCR8 mRNA was not different between the PBMCs of MS patients and normal subjects and its levels did not change with either siRNA or IL-4 treatment. However, CCR4 mRNA transcripts were higher in PBMCs of MS patients compared to PBMCs of normal subjects, yet its expression levels did not change with either siRNA or IL-4 treatment.

Other STAT6-responsive genes, including ADAM8, LTα, and arginase I were analyzed and both mRNA and protein expression were elevated in PBMCs of MS patients compared to normal subjects (Table 1 and Figure 8). ADAM8 is a STAT6-responsive41,42 disintegrin matrix metalloproteinase that may be involved in demyelination.43 LTα is also STAT6-inducible in human leukocytes44 and is a member of the TNF superfamily that has been shown to mediate inflammation and demyelination in mouse models of MS.45,46 Arginase I is expressed both in the CNS and the immune system and is highly inducible by IL-4 through STAT6.47 Apart from participating in the urea cycle, arginase I also plays an important role in both virus-induced35 and autoimmune-mediated demyelination.48 Interestingly, ADAM8, LTα, and arginase I, showed higher inducible mRNA and protein levels in PBMCs of MS patients compared to normal subjects following IL-4 treatment consistent with the fact that they are STAT6 inducible (Table 1 and Figure 8). Furthermore, treatment of normal PBMCs with siRNA against SHP-1 significantly raised the levels of ADAM8, LTα, and arginase I (Table 1). Additionally, transduction of the SHP-1-expressing lentiviral vector resulted in a decrease of ADAM8, LTα, and arginase I expression in PBMCs of MS patients (Table 2).

Other genes not associated with STAT6 activation were also measured (Tables (Tables11 and and2).2). We did not observe any differences in the expression of the cytokine IFN-γ,49 or the chemokine receptor CXCR350,51 between PBMCs of MS patients and normal subjects. In contrast, the expression levels of the STAT1-responsive chemokine IP-10 were elevated in PBMCs of MS patients compared to normal subjects in accord with several studies.52-56 Furthermore, IP-10 mRNA showed a modest but significant increase in PBMCs of normal subjects following treatment with SHP-1 siRNA, but was not inducible by IL-4 treatment. To determine whether effects on the above genes were specific, neither the STAT-independent chemokine MCP-157 nor the housekeeping gene GAPDH showed differences in expression levels between normal subjects and MS patients (Table 1).

DISCUSSION

The present study demonstrates that PBMCs of MS patients express lower levels of the protein tyrosine phosphatase SHP-1. Furthermore, this SHP-1 deficiency corresponds to a diminished expression of promoter II transcripts. Accordingly, PBMCs of MS patients have constitutively higher activated STAT6, a transcription factor that is stringently modulated by SHP-1. In turn, several STAT6-inducible genes that may play a role in the mechanism of inflammatory demyelination are shown to be both higher in MS patients and regulated by SHP-1.

The relevance of the present findings to the pathogenetic mechanisms of MS is suggested by previous reports on signaling molecules in the CNS of MS subjects that are regulated by SHP-1. For instance, pSTAT6 was found to be highly expressed in oligodendrocytes and reactive microglia in active MS lesions compared to cells in white matter of normal subjects or patients with other neurological diseases.5 In animal models of MS, mice that lack SHP-1 show increased constitutive activation of STAT6 and heightened levels of STAT6-inducible genes both in the CNS35 and in peripheral immune cells (personal unpublished observations). Thus, the present study indicates that expression of several genes with confirmed STAT6-responsive elements may have functional significance to the pathophysiology of MS.

The chemokine CCL17/TARC is highly expressed by both T cells and monocytes and binds to the CCR4 and CCR8 chemokine receptors to attract T cells58 and monocytes59 to inflammatory sites. Here, we show that CCL17/TARC is elevated in the PBMCs of MS patients, suggesting that CCL17/TARC may act to further accentuate the infiltration of T cells and monocytes into areas of demyelination. Also, CCL11/eotaxin, which is a potent chemoattractant of monocytes to areas of inflammation,60 was elevated in PBMCs of MS patients and its expression was controlled by SHP-1.

Analysis of other STAT6-responsive genes showed that the matrix metalloproteinase ADAM8 is elevated in PBMCs of MS patients and SHP-1 controls its expression. Proteinases may be involved in the pathogenesis of MS, since these can mediate the proteolysis of extracellular matrix molecules, disrupt the blood–brain barrier, and promote lymphocyte entry into the brain parenchyma. Additionally, ADAM8 was shown to hydrolyze myelin basic protein43 and can therefore directly contribute to demyelination.

Previously, it was shown that LTα mediates inflammation and demyelination both in EAE and the cuprizone models of MS.46,61 In particular, function-blocking antibodies against LTα were shown to prevent EAE.62 Here, we show that LTα, a STAT6-inducible gene,44 is elevated in the PBMCs of MS patients compared to normal subjects. The fact that SHP-1 controls the expression of inflammatory genes like LTα illustrates the potential impact of SHP-1 deficiency in MS patients.

Arginase I is a STAT6-responsive gene that has be shown to be constitutively elevated in the CNS of SHP-1-deficient mice and plays an important role in virus-induced demyelinating disease.35 Additionally, arginase I inhibition results in attenuation of EAE onset and progression.48 Although the mechanism by which arginase I activity in either the CNS or immune systems may promote inflammatory demyelination still remains to be elucidated, its role in MS in light of the present findings should be further investigated.

Apart from STAT6, there are several other transcription factors that are elevated in MS patients and are controlled by SHP-1. In particular, tyrosine-phosphorylated STAT1 (pY-STAT1) that mediates interferon signaling was found to be elevated in MS patients.3,4 We have verified with flow cytometry that pY-STAT1 was increased in PBMCs of MS patients compared to normal subjects (personal unpublished data) and verified that STAT1-inducible genes like IP-10 are elevated in PBMCs of MS patients (Table 1) as previously shown.52-56 SHP-1 has been shown to control STAT1 activation.3,9,63 Thus, lower levels of SHP-1, as seen in PBMCs of MS patients, can provide a potential explanation for the heightened STAT1 activation seen in MS.

Furthermore, the transcription factor NF-κB mediates inflammatory cytokine signaling and is elevated in MS lesions.64 Thus, it may be important that mice genetically lacking SHP-1 show elevated NF-κB activity and increased NF-κB-inducible genes both in CNS glia and in lymphocytes.29,65 Further investigation is needed to determine whether several of the abnormalities seen in MS, including overactive inflammatory transcription factors, can be attributed to the stable deficiency of SHP-1 seen in MS patients.

SHP-1 deficiency has been associated with several immune abnormalities.16 Importantly, several signaling events of antigen receptors on lymphocytes involve tyrosine phosphorylation. Lack of the protein tyrosine phosphatase SHP-1 was shown to effectively increase the activity of the protein tyrosine kinases Src and Lyn in B cells and Lck and Fyn in T cells.66 Absence of SHP-1 in B cells results in increased antigen receptor signaling, polyclonal B cell activation, and autoimmunity.67-69 In addition, several studies have demonstrated that lack of SHP-1 in T cells leads to lower activation threshold and prolonged proliferation.70 In the light that much of the CNS damage seen in MS may be mediated through reactive T cells and increased antibody production, the SHP-1 deficiency seen in MS patients could play a role both in initiating or exacerbating immune responses that cause demyelination.

Importantly, in both the TMEV and the EAE mouse models of MS, lack of SHP-1 leads to more severe disease progression and demyelination.12,13 Furthermore, SHP-1 is highly expressed in oligodendrocytes and astrocytes, and the lack of SHP-1 leads to pronounced Jak/STAT signaling within CNS glia that might be important in oligodendrocyte pathology.10 In support for this role, motheaten mice have reduced myelin basic protein expression and dysmyelination compared to wild-type mice, suggesting that SHP-1 is important in myelin formation and/or maintenance.11 The latter may relate to the preferential expression of STAT6 in oligodendrocytes5 and to important regulatory functions for SHP-1 in these cells, especially during inflammatory events in the white matter. Therefore, it will be important to investigate whether the lower SHP-1 levels seen in the PBMCs of MS patients are also seen in CNS glia within MS lesions.

In this study, the expression levels of SHP-1 both in freshly isolated PBMCs and PBMCs cultured for 1 week in vitro were analyzed. We found that in either freshly isolated or cultured PBMCs, MS patients had a deficient expression of SHP-1 compared to normal subjects. This observation both allowed a determination of the stability of this difference and further subsequent experimental manipulation of considerably increased numbers of cultured cells than was possible using freshly isolated cells. Further, we verified that culturing PBMCs did not differentially affect the proportions of cell types between MS patients and PBMCs of normal subjects, which may have otherwise confounded our analysis. Finally, we document that pSTAT6 levels and STAT6-responsive genes are elevated in cultured PBMCs of MS patients. In keeping with stable SHP-1 differences, freshly isolated PBMCs had similar gene expression patterns of STAT6- and STAT1-responsive genes as cultured PBMCs in that genes like CCL17 and IP-10 were significantly higher in MS patients compared to normal subjects (personal unpublished data).

Two distinct promoters drive the expression of two different SHP-1 transcripts from the SHP-1 gene. Here, we demonstrated that promoter II transcripts, which are more abundantly expressed in hematopoietic cells, are selectively lower in the PBMCs of MS patients compared to normal subjects. Several studies have examined the contribution of genetics in MS71-74 and none have shown any linkage associated with the SHP-1 locus, chromosome 12p12.21 In contrast, numerous reports document the downregulation of the promoter II transcripts in leukemia/lymphoma cell lines and attribute SHP-1 deficiency to epigenetic modifications and in particular CpG methylation of SHP-1 promoter II.14,15 Interestingly, in the context of MS, either viral infections75-79 or inflammation80-83 can cause de novo methylation or hypermethylate CpG promoter sequences resulting in decreased gene expression. In accordance with these reports, preliminary data indicate that treatment of PBMCs of MS patients with the demethylating agent 2′-deoxy-5-azacytidine increase SHP-1 promoter II transcripts to normal levels (personal unpublished observations). Furthermore, a recent study reports that the HTLV-1 Tax protein profoundly suppresses the activity of the SHP-1 promoter II through recruitment of histone deacetylase-1.84 Interestingly, HTLV-1 is a lymphotropic virus that has been associated with CNS-demyelinating disease known as HAM/TSP (HTLV-1-associated myelopathy/tropical spastic paraparesis).85 The observation that lymphotropic viruses may selectively decrease SHP-1 expression lends support to the hypothesis that viral infection, possibly through epigenetic downmodulation of genes, can trigger immune-mediated demyelination.86,87 Whether CpG methylation and/or histone deacetylation lead to stable epigenetic modification of promoter II in MS patients, is responsible for stable deficiency of SHP-1, and is responsible for increased CNS inflammation in MS lesions requires further investigation.

ACKNOWLEDGEMENT

This study was supported in part by research grants from the National Multiple Sclerosis Society (RG2569C5) to Paul T Massa, NIH grant (NS041593) to Paul T Massa, and Serono Inc. to Burk Jubelt, Cornelia Mihai, and Paul T Massa. We also thank Dr Nick J Gonchoroff for his expertise in flow cytometry/cell sorting performed in this study and Dr Gerold Feuer for assistance in design and production of lentivirus expression vectors.

References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–952. [PubMed]
2. Kornek B, Lassmann H. Neuropathology of multiple sclerosis—new concepts. Brain Res Bull. 2003;61:321–326. [PubMed]
3. Gobin SJ, Montagne L, Van Zutphen M, et al. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia. 2001;36:68–77. [PubMed]
4. Frisullo G, Angelucci F, Caggiula M, et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing–remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res. 2006;84:1027–1036. [PubMed]
5. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol. 2004;55:46–57. [PubMed]
6. David M, Romero G, Zhang ZY, et al. In vitro activation of the transcription factor ISGF3 by interferon alpha involves a membrane-associated tyrosine phosphatase and tyrosine kinase. J Biol Chem. 1993;268:6593–6599. [PubMed]
7. Jiao H, Berrada K, Yang W, et al. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 1996;16:6985–6992. [PMC free article] [PubMed]
8. Frank C, Burkhardt C, Imhof D, et al. Effective dephosphorylation of Src substrates by SHP-1. J Biol Chem. 2004;279:11375–11383. [PubMed]
9. Massa PT, Wu C. The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells. J Immunol. 1996;157:5139–5144. [PubMed]
10. Massa PT, Saha S, Wu C, et al. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia. 2000;29:376–385. [PubMed]
11. Massa PT, Wu C, Fecenko-Tacka K. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. J Neurosci Res. 2004;77:15–25. [PubMed]
12. Massa PT, Ropka SL, Saha S, et al. Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler’s murine encephalomyelitis virus. J Virol. 2002;76:8335–8346. [PMC free article] [PubMed]
13. Deng C, Minguela A, Hussain RZ, et al. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol. 2002;168:4511–4518. [PubMed]
14. Zhang Q, Raghunath PN, Vonderheid E, et al. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157:1137–1146. [PubMed]
15. Oka T, Yoshino T, Hayashi K, et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Amour J Pathol. 2001;159:1495–1505. [PubMed]
16. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997;15:302–307. [PubMed]
17. Wu C, Sun M, Liu L, et al. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003;306:1–12. [PubMed]
18. Feng X, Petraglia AL, Chen M, et al. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002;129:205–215. [PubMed]
19. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 1995;27:165–173. [PubMed]
20. Martin A, Tsui HW, Shulman MJ, et al. Murine SHP-1 splice variants with altered Src homology 2 (SH2) domains. Implications for the SH2-mediated intramolecular regulation of SHP-1. J Biol Chem. 1999;274:21725–21734. [PubMed]
21. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12–p13. Mol Cell Biol. 1992;12:836–846. [PMC free article] [PubMed]
22. Tsui HW, Hasselblatt K, Martin A, et al. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem. 2002;269:3057–3064. [PubMed]
23. Ruchusatsawat K, Wongpiyabovorn J, Shuangshoti S, et al. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J Mol Med. 2006;84:175–182. [PubMed]
24. Xu Y, Banville D, Zhao HF, et al. Transcriptional activity of the SHP-1 gene in MCF7 cells is differentially regulated by binding of NF-Y factor to two distinct CCAAT-elements. Gene. 2001;269:141–153. [PubMed]
25. Wlodarski P, Zhang Q, Liu X, et al. PU.1 activates transcription of SHP-1 gene in hematopoietic cells. J Biol Chem. 2007;282:6316–6323. [PubMed]
26. Leon F, Cespon C, Franco A, et al. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling. Leukemia. 2002;16:1470–1477. [PubMed]
27. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121–127. [PubMed]
28. Christophi GP, Isackson PJ, Blaber S, et al. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem. 2004;91:1439–1449. [PubMed]
29. Massa PT, Wu C. Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J Interferon Cytokine Res. 1998;18:499–507. [PubMed]
30. Wrzesinski S, Seguin R, Liu Y, et al. HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses. 2000;16:1771–1776. [PubMed]
31. Hudson CA, Christophi GP, Cao L, et al. Regulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1. Neuron Glia Biol. 2006;2:235–246. [PMC free article] [PubMed]
32. Chang L, Gusewitch GA, Chritton DB, et al. Rapid flow cytometric assay for the assessment of natural killer cell activity. J Immunol Methods. 1993;166:45–54. [PubMed]
33. Haque SJ, Harbor P, Tabrizi M, et al. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem. 1998;273:33893–33896. [PubMed]
34. Hanson EM, Dickensheets H, Qu CK, et al. Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem. 2003;278:3903–3911. [PubMed]
35. Bonaparte KL, Hudson CA, Wu C, et al. Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia. Glia. 2006;53:827–835. [PubMed]
36. Kamata T, Yamashita M, Kimura M, et al. src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest. 2003;111:109–119. [PMC free article] [PubMed]
37. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006;27:48–55. [PubMed]
38. Wirnsberger G, Hebenstreit D, Posselt G, et al. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36:1882–1891. [PMC free article] [PubMed]
39. Narikawa K, Misu T, Fujihara K, et al. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2004;149:182–186. [PubMed]
40. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol. 2001;24:755–761. [PubMed]
41. Richens J, Fairclough L, Ghaemmaghami AM, et al. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology. 2007;212:29–38. [PubMed]
42. King NE, Zimmermann N, Pope SM, et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol. 2004;31:257–265. [PubMed]
43. Amour A, Knight CG, English WR, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002;524:154–158. [PubMed]
44. Worm MM, Tsytsykova A, Geha RS. CD40 ligation and IL-4 use different mechanisms of transcriptional activation of the human lymphotoxin alpha promoter in B cells. Eur J Immunol. 1998;28:901–906. [PubMed]
45. Plant SR, Arnett HA, Ting JP. Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination. Glia. 2005;49:1–14. [PubMed]
46. Plant SR, Iocca HA, Wang Y, et al. Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein. J Neurosci. 2007;27:7429–7437. [PubMed]
47. Pauleau AL, Rutschman R, Lang R, et al. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol. 2004;172:7565–7573. [PubMed]
48. Xu L, Hilliard B, Carmody RJ, et al. Arginase and autoimmune inflammation in the central nervous system. Immunology. 2003;110:141–148. [PubMed]
49. Nguyen KB, Watford WT, Salomon R, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science. 2002;297:2063–2066. [PubMed]
50. Kivisakk P, Trebst C, Liu Z, et al. T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol. 2002;129:510–518. [PubMed]
51. Fox RJ, Kivisakk P, Lee JC, et al. Chemokine receptors as biomarkers in multiple sclerosis. Dis Markers. 2006;22:227–233. [PubMed]
52. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807–815. [PMC free article] [PubMed]
53. Simpson JE, Newcombe J, Cuzner ML, et al. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2000;26:133–142. [PubMed]
54. Salmaggi A, Gelati M, Dufour A, et al. Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res. 2002;22:631–640. [PubMed]
55. Tanuma N, Sakuma H, Sasaki A, et al. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006;112:195–204. [PubMed]
56. Omari KM, John GR, Sealfon SC, et al. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain. 2005;128(Pt 5):1003–1015. [PubMed]
57. Goebeler M, Gillitzer R, Kilian K, et al. Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood. 2001;97:46–55. [PubMed]
58. Wenzel J, Henze S, Worenkamper E, et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol. 2005;124:1241–1248. [PubMed]
59. Belperio JA, Dy M, Murray L, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol. 2004;173:4692–4698. [PubMed]
60. Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169:2712–2718. [PubMed]
61. Suen WE, Bergman CM, Hjelmstrom P, et al. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med. 1997;186:1233–1240. [PMC free article] [PubMed]
62. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med. 1990;172:1193–1200. [PMC free article] [PubMed]
63. Yetter A, Uddin S, Krolewski JJ, et al. Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem. 1995;270:18179–18182. [PubMed]
64. Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol. 1999;155:1433–1438. [PubMed]
65. Khaled AR, Butfiloski EJ, Sobel ES, et al. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B. Cell Immunol. 1998;185:49–58. [PubMed]
66. Unkeless JC, Jin J. Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol. 1997;9:338–343. [PubMed]
67. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity. 1995;2:13–24. [PubMed]
68. Huang ZY, Hunter S, Kim MK, et al. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukoc Biol. 2003;73:823–829. [PubMed]
69. Pao LI, Lam KP, Henderson JM, et al. B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity. 2007;27:35–48. [PubMed]
70. Johnson KG, LeRoy FG, Borysiewicz LK, et al. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J Immunol. 1999;162:3802–3813. [PubMed]
71. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005;6:375–387. [PubMed]
72. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851–862. [PubMed]
73. Karpuj MV, Steinman L, Oksenberg JR. Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics. 1997;1:21–28. [PubMed]
74. Asimakopoulos FA, Hinshelwood S, Gilbert JG, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene. 1997;14:1215–1222. [PubMed]
75. Osawa T, Chong JM, Sudo M, et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res. 2002;93:1195–1200. [PubMed]
76. Muller K, Heller H, Doerfler W. Foreign DNA integration. Genome-wide perturbations of methylation and transcription in the recipient genomes. J Biol Chem. 2001;276:14271–14278. [PubMed]
77. de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a ‘hot spot’ for hypermethylation in human neoplasia. Proc Natl Acad Sci USA. 1988;85:5693–5697. [PubMed]
78. Mikovits JA, Young HA, Vertino P, et al. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol. 1998;18:5166–5177. [PMC free article] [PubMed]
79. Amara K, Trimeche M, Ziadi S, et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer. 2007;121:2693–2702. [PubMed]
80. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007;67:5583–5586. [PubMed]
81. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007;67:946–950. [PubMed]
82. Rouleau J, MacLeod AR, Szyf M. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem. 1995;270:1595–1601. [PubMed]
83. Hmadcha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999;190:1595–1604. [PMC free article] [PubMed]
84. Cheng J, Kydd AR, Nakase K, et al. Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood. 2007;110:2110–2120. [PubMed]
85. Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol. 2006;5:1068–1076. [PubMed]
86. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–681. [PubMed]
87. Scarisbrick IA, Rodriguez M. Hit-Hit and hit-Run: viruses in the playing field of multiple sclerosis. Curr Neurol Neurosci Rep. 2003;3:265–271. [PubMed]